Carol Wysham, MD
Endocrinology, Diabetes & Metabolism · Spokane, WANPI 1457344541
Payments from drug & device makers
Across 1,162 payments — averaging $1354.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$451K
- AbbVie$294K
- Novo Nordisk$185K
- Novo Nordisk AS$172K
- Abbott$124K
- Sanofi-aventis U.S. LLC$114K
- plus $233K from 21 others
Across 13 payments — averaging $2464.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$29K
- Sanofi-aventis U.S. LLC$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 58 | $451,105 |
| AbbVie(2 entities) | 66 | $293,831 |
| Novo Nordisk | 128 | $185,203 |
| Novo Nordisk AS | 499 | $172,188 |
| Abbott | 171 | $124,185 |
| Sanofi-aventis U.S. LLC | 45 | $114,339 |
| Vanda Pharmaceuticals Inc. | 9 | $45,765 |
| Lilly USA, LLC | 53 | $40,325 |
| Johnson & Johnson | 31 | $34,310 |
| Gilead | 5 | $26,384 |
| Corcept Therapeutics | 20 | $22,689 |
| Regeneron | 5 | $20,348 |
| Bayer | 12 | $14,569 |
| Mannkind Corporation | 12 | $5,950 |
| Boehringer Ingelheim | 11 | $5,669 |
| Cequr Corporation | 4 | $4,861 |
| Dexcom, Inc. | 2 | $3,360 |
| Astrazeneca UK Limited | 5 | $2,709 |
| AstraZeneca | 5 | $2,385 |
| Amgen | 1 | $1,500 |
| Medtronic(2 entities) | 6 | $602 |
| Merck | 3 | $331 |
| Lexicon Pharmaceuticals, Inc. | 4 | $248 |
| Janssen Scientific Affairs, LLC | 3 | $233 |
| Insulet Corporation | 1 | $156 |
| Tandem Diabetes Care, Inc. | 1 | $73 |
| Kyowa Kirin, Inc. | 2 | $66 |
How this compares
$1,573,384 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Spokane
- Lynn KohlmeierSpokane$518K
- Harold CathcartSpokane$159K
- Mihaela CosmaSpokane$5K
- Ronald BrazgRenton$17.9M
- Frances BroylesSeattle$5.6M
- Leslie KlaffRenton$2.8M
- Carla GreenbaumSeattle$2.6M
- Irl HirschSeattle$2.4M
- William HagopianSeattle$2.1M
- Michael SchwartzSeattle$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.